ROME (ITALPRESS) – Laura Nocerino has assumed the role of Rare BU Head of Takeda Italy becoming a member of the Leadership Team. This appointment represents a significant moment for the company. Nocerino, in fact, had previously held roles of increasing responsibility, contributing to the success of several therapeutic areas in Takeda Italy. Her return, not only enhances her already recognized experience in the field of rare diseases, but also represents a confirmation of the deep bond with the company, whose culture and values she knows thoroughly.Experience and responsibility in the field of rare diseases are among the key elements that characterize her work. Most recently, Laura Nocerino held the position of Commercial Lead Hematology & CAR T at Bristol Myers Squibb (BMS). During her tenure, she led the successful launch of two CAR T therapies and directed the entire Hematology Unit, which included the areas of Multiple Myeloma, Non-Hodgkin’s Lymphoma, Beta Thalassemia, Myelodysplasia, and Myelofibrosis. He also gained solid experience in the pharmaceutical industry, collaborating with leading companies and working in numerous therapeutic areas, including Rare Diseases, Advanced Therapies (ATMP), Cellular Therapies, Oncohematology, Gastroenterology and IBD, Respiratory Diseases, Diabetes, Tissue Surgery, Osteoporosis, Urology, and Psychiatry.In his career path at Takeda Italy, he held instrumental positions as Marketing Lead Immunology IBD and later GI Rare Lead. His deep knowledge of the company, its core principles and culture, will consolidate the growth process already underway, strengthening Takeda’s commitment to bringing therapeutic innovations to the treatment of rare diseases. A commitment that places Takeda Italia at the forefront of the path to support patients who do not yet have access to life-saving therapies: today, more than 60 percent of the pipeline concerns a rare disease. There are, in addition, more than 40 products developed for 13 diseases, with a focus on rare hematology and the development of innovative molecules for therapeutic areas where “unmet need” still exists. “It is an honor and a pleasure to return to Takeda Italia, a company that has represented a fundamental chapter in my professional and personal journey. I am thrilled to take over the leadership of the Rare BU at a crucial time, where my goal will be to help raise awareness about rare diseases by accelerating the development of innovative therapeutic solutions for patients. Passion for our mission and commitment to people have consistently guided my daily efforts, and I am ready to contribute to the growth of the company together with an extraordinary team,” comments Laura Nocerino, Rare BU Head, Takeda Italy. “We are thrilled to welcome back Laura Nocerino, a professional who deeply knows our reality and values. Her return represents an important asset to our team, bringing with her a vast experience and a strong connection with the principles that guide Takeda. These elements will be fundamental to successfully lead our Rare Diseases Business Unit,” says Anna Maria Bencini, General Manager, Takeda Italy.-photo press office Havas-(ITALPRESS).
